Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Applied Materials -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (41981)	2/9/2001 6:06:32 PM
From: Ian@SI	Read Replies (1) \| Respond to of 70976

OT to Sam The approvable letter on Monday was for 2 completely different retinal diseases - pathological myopia being the largest with 50,000 new cases annually worldwide. The Thursday move came from the release of additional Phase III results on Wednesday which showed efficacy for the Occult form of AMD (Age related Macular Degeneration) was the significant finding as it applies to TWICE as many cases annually as the Classic form of AMD. Specifically, rather than 100,000 new cases annually requiring about 3 treatments in year 1 and another 2 during year 2; that number is now 350,000+ that will be covered by the expanded label. ... once, and if, the FDA and other regulatory bodies approve the expansion. (this is expected to happen within about a year, perhaps a little less). The stock is trading at about 40% of its 52 week high even after Thursday's very nice move. I expect it to set a new high within a year - perhaps even this year. Ian.,